The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics

BACKGROUND: Interferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective. OBJECTIVE: To review the rationale, design, and baseline characteristics of the CombiRx s...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lindsey, JW, Scott, TF, Lynch, SG, Cofield, SS, Nelson, F, Conwit, R, Gustafson, T, Cutter, GR, Wolinsky, JS, Lublin, FD
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3384544/
https://ncbi.nlm.nih.gov/pubmed/22754793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2012.01.006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky